Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts
This article was originally published in The Tan Sheet
Executive Summary
Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.
You may also be interested in...
Oxytrol OTC Success Depends On Driving Behavioral Changes
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.
Oxytrol OTC Success Depends On Driving Behavioral Changes
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.
Oxytrol OTC Success Depends On Driving Behavioral Changes
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.